Compare · DHR vs NIKI
DHR vs NIKI
Side-by-side comparison of Danaher Corporation (DHR) and Niki BioSolutions Inc. (NIKI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DHR and NIKI operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- DHR is the larger of the two at $155.03B, about 33602.5x NIKI ($4.6M).
- DHR has been more active in the news (24 items in the past 4 weeks vs 4 for NIKI).
- DHR has more recent analyst coverage (25 ratings vs 0 for NIKI).
- Company
- Danaher Corporation
- Niki BioSolutions Inc.
- Price
- -
- -
- Market cap
- $155.03B
- $4.6M
- 1M return
- -3.93%
- -
- 1Y return
- -2.95%
- -
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 24
- 4
- Recent ratings
- 25
- 0
Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
Niki BioSolutions Inc.
Niki BioSolutions is a clinical-stage life sciences company focused on addressing unmet medical needs by developing high-quality genomic and biomarker testing solutions to healthcare providers, research institutions, and life sciences organizations. Through its CLIA-certified, CAP-accredited laboratory, the Company combines proprietary technologies with scientific rigor to support precision medicine across a range of therapeutic areas. Niki BioSolutions collaborates with leading academic centers, disease foundations, and biopharmaceutical companies.
Latest DHR
- Danaher Collaborates with Microsoft to Make Scientific Instruments Agentically Connected and Laboratories More Intelligent
- Executive Vice President Gregory M Milosevich covered exercise/tax liability with 58 shares, decreasing direct ownership by 0.26% to 22,309 units (SEC Form 4)
- SVP-Chief Legal Officer Jonathan Leiken covered exercise/tax liability with 1,122 shares, decreasing direct ownership by 9% to 11,424 units (SEC Form 4)
- President & CEO Sawyer Montgomery Julie A covered exercise/tax liability with 261 shares, decreasing direct ownership by 1% to 21,960 units (SEC Form 4)
- SVP, Chief Strategy Officer Shashanka Muppaneni covered exercise/tax liability with 122 shares, decreasing direct ownership by 2% to 5,779 units (SEC Form 4)
- EVP & Chief Financial Officer Matthew E Gugino covered exercise/tax liability with 1,018 shares, decreasing direct ownership by 9% to 10,383 units (SEC Form 4)
- Director Daniel L Comas was granted 282 shares (SEC Form 4)
- SVP, Chief HR Officer Heathre T Moler covered exercise/tax liability with 37 shares, decreasing direct ownership by 0.69% to 5,319 units (SEC Form 4)
- Director Robert Hershberg was granted 282 shares (SEC Form 4)
- Executive Vice President Milosevich Gregory M sold $484,302 worth of shares (2,100 units at $230.62), decreasing direct ownership by 9% to 22,367 units (SEC Form 4)